Skip to main content
eScholarship
Open Access Publications from the University of California

Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. Arrhizus infection

  • Author(s): Gebremariam, T
  • Alkhazraji, S
  • Lin, L
  • Wiederhold, NP
  • Garvey, EP
  • Hoekstra, WJ
  • Schotzinger, RJ
  • Patterson, TF
  • Filler, SG
  • Ibrahim, AS
  • et al.

Published Web Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571349/
No data is associated with this publication.
Abstract

Copyright © 2017 American Society for Microbiology. All Rights Reserved. We compared prophylactic or continuous therapy with the investiga-tional drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus. In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item